Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...

The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 ...

Casgevy isn’t a simple pill or injection. The treatment, made by Vertex Pharmaceuticals, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

Casgevy is a one-time therapy that uses CRISPR/Cas9 gene-editing technology to modify a patient’s haematopoietic stem cells. The process targets the BBCL11A gene to increase foetal haemoglobin ...

Casgevy first launched in the US, followed by Luxembourg five months later, and then Bahrain in June 2024. When compared to the average launch sequence of haematological agents that fall under the ...

Casgevy modifies patients’ DNA to correct the underlying cause of their illness. In a clinical trial, it eliminated pain crises for 29 out of 31 patients with sickle cell.

For Casgevy, the drug is a personalised one-off treatment made from tweaking the patient's own cells - that makes it expensive and time-consuming. Add in the cost of research and development ...